Nektar Rezpegaldesleukin Shows 52-Week Alopecia Results
SAN FRANCISCO, April 20, 2026 Nektar Therapeutics has reported compelling 52-week topline results from the Phase 2b REZOLVE-AA trial,...
Rezpegaldesleukin
Advertisement
Rezpegaldesleukin Shows Strong Phase 2b Results in AD
San Francisco, USA | March 28, 2026 Phase 2b Data Demonstrates Strong Clinical Efficacy Nektar Therapeutics has announced compelling...
Nektar Therapeutics Reports Phase 2b Rezpegaldesleukin Data
San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...
Nektar Raises $460M to Advance Immunotherapy Pipeline
SAN FRANCISCO, Feb. 13, 2026 — Nektar Therapeutics announced the successful closing of a $460 million underwritten public offering,...
Advertisement
